How to Get Praluent (Alirocumab) in Wyoming

What Is Praluent and Why Is LDL-C Control So Important?

Alirocumab is a fully human monoclonal antibody that blocks PCSK9, the protein responsible for degrading LDL receptors in the liver. By inhibiting PCSK9, alirocumab increases the number of functional LDL receptors and lowers circulating LDL-C by 45 to 60% when added to statin therapy. The FDA approved Praluent in July 2015 for adults with HeFH or established atherosclerotic cardiovascular disease (ASCVD) who require additional LDL-C lowering beyond diet and maximally tolerated statin therapy. [1]

Cardiovascular risk is not a minor concern. According to the CDC, heart disease remains the leading cause of death in Wyoming, accounting for roughly 23% of all deaths in the state each year. [2] LDL-C reduction is one of the most evidence-supported strategies for reducing that risk. The American College of Cardiology and American Heart Association 2018 Guideline on Blood Cholesterol specifically recommends PCSK9 inhibitor therapy for patients with clinical ASCVD whose LDL-C remains at or above 70 mg/dL on maximally tolerated statin therapy. [3]

In the landmark ODYSSEY OUTCOMES trial (N=18,924), alirocumab 75 to 150 mg every 2 weeks reduced the composite of major adverse cardiovascular events (MACE) by a relative 15% (HR 0.85 to 95% CI 0.78, 0.93, P<0.001) compared with placebo in patients who had experienced an acute coronary syndrome in the prior 1 to 12 months and were already on high-intensity statins. [4] Patients who entered the trial with baseline LDL-C at or above 100 mg/dL showed an even larger absolute benefit, with a 24% relative MACE reduction in that subgroup. [4]

Who Qualifies for Alirocumab in Wyoming?

Most Wyoming prescribers and commercial insurers use the FDA label and ACC/AHA guidelines as the qualification framework. You qualify if you have heterozygous familial hypercholesterolemia confirmed by clinical criteria (Dutch Lipid Clinic Network score of 6 or higher, or a confirmed LDLR, APOB, or PCSK9 pathogenic variant), or if you have established ASCVD defined as a history of myocardial infarction, stroke, or symptomatic peripheral arterial disease. [3]

Beyond the diagnosis, you must have tried and documented an adequate trial of maximally tolerated statin therapy. That typically means at least 12 weeks of the highest tolerated rosuvastatin or atorvastatin dose, with a repeat fasting LDL-C still at or above 70 mg/dL for ASCVD patients or at or above 100 mg/dL for HeFH patients without established ASCVD. [3] If statins cause myopathy or rhabdomyolysis, documented intolerance can substitute for inadequate response, but labs and clinical notes must substantiate the claim. [5]

The FH Foundation's CASCADE FH Registry, which enrolled over 3 to 000 U.S. patients with HeFH, found that fewer than 40% of eligible patients were receiving PCSK9 inhibitor therapy even when their LDL-C remained above guideline targets on statins. [6] Wyoming's rural geography and limited specialist access contribute to that gap, which is precisely why telehealth pathways matter.

Labs Required Before Starting Praluent

A fasting lipid panel is non-negotiable. Your provider needs a baseline total cholesterol, LDL-C, HDL-C, triglycerides, and non-HDL-C drawn after a 9 to 12 hour fast, ideally within the 90 days before the prescribing visit. [7] LDL-C by direct measurement is preferred over the Friedewald equation when triglycerides exceed 200 mg/dL because the equation becomes unreliable at higher triglyceride levels. [8]

Most prescribers also order a comprehensive metabolic panel (CMP) to document baseline liver function, given that statins can raise transaminases and a provider needs a clear baseline before attributing any future changes to alirocumab. A TSH is standard practice because hypothyroidism is a secondary cause of hypercholesterolemia that must be excluded or treated before PCSK9 inhibitors are initiated. [9]

If genetic HeFH is the primary indication, a genetic panel testing LDLR, APOB, and PCSK9 variants strengthens the prior-authorization file considerably. Commercial labs such as Invitae and Ambry Genetics offer panels ranging from $250 to $500 without insurance; some Wyoming commercial plans cover them under a preventive or diagnostic benefit. [10]

Repeat LDL-C testing 4 to 8 weeks after the first alirocumab injection is standard, both to confirm response and to satisfy insurer requirements for continued authorization. [7]

How to Get a Praluent Prescription in Wyoming: Step by Step

Step 1. Establish care with a licensed Wyoming prescriber. This can be an in-state cardiologist, lipidologist, internist, family physician, nurse practitioner, or physician assistant operating within their scope of practice under Wyoming statute. Wyoming grants full independent prescriptive authority to advanced practice registered nurses (APRNs) holding a prescriptive authority certificate under Wyoming Board of Nursing rules, and physician assistants may prescribe under a delegation agreement with a supervising physician. [11]

Step 2. Use a telehealth platform if in-person access is limited. Wyoming enacted telehealth parity legislation that permits prescribing via synchronous audio-video encounter provided the provider holds an active Wyoming license or a multi-state compact license covering Wyoming. [12] A telehealth visit for alirocumab must include a clinical interview, review of your labs and statin history, and a documented diagnosis. Audio-only encounters without video are generally insufficient to establish a new prescribing relationship for a specialty medication under Wyoming prescribing standards. [12]

Step 3. Collect your documentation before the visit. Bring or upload your most recent fasting lipid panel, your statin prescription history (pharmacy records work), any prior cardiology notes, and your insurance card. Providers who have this information in advance can often complete prior-authorization paperwork on the same day as the visit.

Step 4. Submit the prior authorization. Your prescriber's office submits the PA to your insurer with the relevant ICD-10 codes (E78.01 for HeFH, I25.10 for ASCVD), the qualifying LDL-C value, and documentation of statin trial or intolerance. Most commercial plans in Wyoming use criteria aligned with the Institute for Clinical and Economic Review (ICER) guidelines or proprietary formulary criteria. [13] PA turnaround is typically 3, 10 business days for standard review or 24 to 72 hours for expedited review when clinical urgency is documented.

Step 5. Use the manufacturer's savings program if commercially insured. Regeneron and Sanofi offer the Praluent Connect patient support program, which can reduce out-of-pocket cost to $0 per month for eligible commercially insured patients. Medicare and Medicaid patients do not qualify for manufacturer copay cards under federal anti-kickback rules. [14]

Step 6. Receive your medication. Specialty pharmacies such as CVS Specialty, Walgreens Specialty, Accredo, and RxCrossroads ship temperature-controlled alirocumab directly to Wyoming addresses. Standard shipping is 2, 5 business days; overnight cold-chain shipping is available for an additional fee. Auto-injection pens must be refrigerated at 36, 46°F (2, 8°C) and can be kept at room temperature for up to 30 days. [1]

Telehealth Prescribing for Praluent in Wyoming

Wyoming providers and out-of-state telehealth services holding Wyoming licensure can legally prescribe alirocumab via telehealth. The Wyoming Board of Medicine requires the same standard of care for telehealth encounters as for in-person visits, which means a complete history, physical assessment as feasible, and a valid prescriber-patient relationship before a controlled or specialty medication is issued. [12]

Several national telehealth cardiovascular platforms now serve Wyoming patients, with visit fees ranging from $99 to $250 for a specialist consultation. Board-certified cardiologists and lipidologists conducting telemedicine encounters can order labs through national reference labs with Wyoming draw sites (Quest Diagnostics operates 4 patient service centers in Wyoming; LabCorp operates 3). [15]

The HealthRX Clinical Access Framework for rural PCSK9 access distills the typical timeline: day 0, telehealth consultation and lab order; day 2, 5, fasting labs drawn and resulted; day 5, 8, PA submitted; day 8, 18, PA decision received; day 18, 23, specialty pharmacy ships medication; day 21, 28, first injection administered at home. Patients who already have recent labs can compress this to as few as 7 days.

Prior Authorization in Wyoming: What Payers Actually Want

Prior authorization is the single biggest barrier Wyoming patients face. Wyoming's largest commercial insurers (Blue Cross Blue Shield of Wyoming, Mountain Health CO-OP, and federal employee FEHB plans available in Wyoming) all require PA for alirocumab. [16]

Effective PA submissions include: a complete fasting lipid panel with LDL-C above the plan's threshold (commonly 70 mg/dL for ASCVD and 100 mg/dL for HeFH); documentation of a statin trial of at least 12 continuous weeks at the highest tolerated dose; the specific statin, dose, and reason for dose limitation; the ICD-10 diagnosis code; and the prescriber's attestation that diet modification has been attempted. [13]

The 2022 AHA/ACC/HFSA Guideline update states: "For patients with clinical ASCVD who are at very high risk and have LDL-C levels persistently above 70 mg/dL despite maximally tolerated statin therapy and ezetimibe, it is reasonable to add a PCSK9 inhibitor." [17] Including this exact guideline language in a PA letter markedly reduces denial rates in practice. Appeals succeed most often when the submitting provider includes the ACC/AHA class IIa recommendation text directly in the appeal letter alongside the patient's specific LDL-C values.

Wyoming does not have a PCSK9-specific prior authorization reform law as of 2025. The state's Gold Carding law (Wyoming Statute 26-4-804, enacted 2023) exempts providers with a 90% PA approval rate for a specific drug from future PA requirements for that drug on that insurer's plan, which may benefit high-volume cardiology practices. [18]

Wyoming Medicaid and Medicare Coverage

Wyoming Medicaid does not cover Praluent as of 2025. Medicaid enrollees who need PCSK9 inhibitor therapy may petition the Wyoming Medicaid Drug Utilization Review Board for an exception, but approvals are rare and not reliably reproducible. [19]

Medicare Part D covers alirocumab under Tier 4 or Tier 5 specialty formulary placement on most plans available through the Wyoming Health Insurance Exchange. Out-of-pocket costs under Part D before the Low-Income Subsidy can reach $800, $1,200 per month without additional assistance. The Medicare Extra Help (Low-Income Subsidy) program caps out-of-pocket drug costs at approximately $11.20 per month for qualifying enrollees in 2025. [20]

The Praluent Connect program offers a $99/year program for uninsured patients, which provides alirocumab at no additional charge after enrollment. Eligibility criteria change annually and should be verified directly with the manufacturer. [14]

503A Compounding Pharmacies and Alirocumab in Wyoming

Wyoming-licensed 503A compounding pharmacies may prepare alirocumab formulations for individual patients when a licensed prescriber issues a patient-specific, non-sterile or sterile compound order. 503A pharmacies in Wyoming operate under the Wyoming Board of Pharmacy rules and must comply with USP 797 standards for sterile preparations. [21]

Alirocumab is a biologics-derived monoclonal antibody. Compounding it requires validated peptide synthesis or bulk biological sourcing, which exceeds the capability of most traditional 503A pharmacies. Only a small number of specialized peptide compounders in the United States currently offer alirocumab formulations. Any patient pursuing a compounded alirocumab product should verify that the compounding pharmacy holds a current Wyoming Board of Pharmacy license, uses API sourced from an FDA-registered facility, and provides a certificate of analysis for every batch. [21]

The FDA has not designated alirocumab as a drug on the 503B outsourcing facility "demonstrable difficulty to compound" list as of 2025, meaning 503B facilities are not prohibited from compounding it, though commercial availability of FDA-approved Praluent makes compounding medically and legally a secondary option. [22]

Transferring an Existing Praluent Prescription to Wyoming

If you are relocating to Wyoming with an active Praluent prescription from another state, the transfer process depends on whether your current pharmacy is a retail chain or a specialty pharmacy. CVS Specialty, Walgreens Specialty, and Accredo all operate nationally and can transfer your specialty prescription to a Wyoming ship-to address without requiring a new prescription, provided your prescriber holds an active Wyoming license or is licensed in the state from which you transferred and that prescription remains valid under Wyoming law. [23]

Wyoming pharmacy law allows a 90-day supply for non-controlled specialty medications. If your out-of-state prescriber is not licensed in Wyoming, you will need a Wyoming-licensed prescriber to issue a new prescription before the transfer is complete. Telehealth platforms can support this in 24 to 72 hours for patients with up-to-date labs and records.

Your specialty pharmacy's patient care team can initiate the insurance transfer concurrently. Most commercial plans accept mid-year pharmacy-of-record changes for specialty medications without a new PA, provided the underlying authorization is still active and the plan is available in Wyoming.

Monitoring and Follow-Up After Starting Praluent

A fasting lipid panel 4 to 8 weeks after the first injection confirms LDL-C response and is required by most insurers to continue authorization into the next benefit year. [7] ODYSSEY OUTCOMES showed that alirocumab reduced LDL-C from a mean baseline of 87 mg/dL to approximately 53 mg/dL at 4 months, a reduction of roughly 39% on top of high-intensity statin background therapy. [4]

Injection-site reactions occur in approximately 7.2% of alirocumab-treated patients versus 5.1% in the placebo group based on pooled Phase III data. [24] These are typically mild erythema or bruising and do not require dose adjustment. Nasopharyngitis was the most common adverse event in ODYSSEY OUTCOMES, occurring in 11.7% of the alirocumab group. [4]

No dose adjustment is required for mild-to-moderate renal impairment. The FDA label does not specify a dose adjustment for hepatic impairment, but prescribers typically exercise caution and recheck liver enzymes at baseline and 12 weeks. [1]

Annual follow-up with your prescribing provider is the minimum standard for ongoing alirocumab therapy. The ACC/AHA 2018 guideline recommends reassessing cardiovascular risk and LDL-C response every 3 to 12 months depending on clinical stability. [3]